Drug intelligence / Profile preview

VM-206

Development stage: Unknown
Lead developer: Reyon Pharmaceutical
Modality: Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

VM-206 is a therapeutic vaccine developed by Viromed, Inc. (now associated with REYON PHARMACEUTICAL Co., Ltd.) targeting HER2-positive cancers. It functions as a recombinant vector vaccine and shared antigen vaccine designed to modulate **HER2** (receptor tyrosine-protein kinase erbB-2), eliciting an immune response against HER2-expressing tumor cells, with preclinical evidence of activity against breast and ovarian tumors.[3][7][11]

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on VM-206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VM-206.

Explore the full profile